About Ocular Therapeutix Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ocutx.com/
Frequently Asked Questions
What is the 52-week range for OCUL?
The 52-week high is $16.44 and the 52-week low is $6.23.
What is the P/E ratio for OCUL?
The P/E ratio data is currently unavailable.
What is the dividend yield for OCUL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -59.87%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -579.10%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.95.
Analyst Recommendation Trends
Wall Street analyst consensus for OCUL over the last few months:
Latest OCUL News
Ocular Therapeutix (OCUL) Stock Still Looks Pricey As 145% Gain Draws Scrutiny
Ocular Therapeutix has delivered a steep 144.6% gain over the past three years, yet the stock is currently well off recent highs. That puts fresh focus on a basic question: Is the price investors see today adequately anchored to the company’s sales, given where the business is in its development path? The share price has climbed 144.6% over three years. This makes the link between that move and Ocular Therapeutix’s sales base a key issue for anyone reassessing the story now. The AXPAXLI...
3 of Wall Street’s Favorite Stocks That Fall Short
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
OCUL Stock On Track For Worst Week In 2.5 Years As Rivals Raise The Bar In Wet AMD
OCUL stock selloff began on Monday after Kodiak Sciences and 4D Molecular posted updates from clinical trials of their eye-disease drugs.
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain. This might have investors contemplating their next move.
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026. Upcoming Investor Conference: Chardan 10th Annual Healthcare Conference:Date: Tuesday, October 20, 2026Fireside Chat: 9:45 AM ETPresenter: Pravin U. Dugel, MD, Executive Chairman, President and CEOLocation: Ne
Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
OCUL’s selloff on Monday was spurred by clinical updates from competitors on their wet AMD treatments.
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughly 760,000 people and claw back billions in subsidies.
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency. Ocular Therapeutix (NASDAQ:OCUL) operates squarely at this intersection, pioneering bioresorbable hydrogel delivery systems designed to fundamentally alter how chronic retinal diseases are treated. The company’s core […]
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment with the Food and Drug Administration on the company’s planned submission packag
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listin
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $25 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $25 price target.
Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
Healthcare stocks were falling pre-bell Tuesday, with the State Street Health Care Select Sector SPD
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company’s application for repeat dosing Commercial readiness accelerates ahead of potential 2027 launch as AXPAXLI is well positioned to pote
Ocular Therapeutix Announces Completion Of Pre-NDA Meeting With FDA For Investigational Product Candidate AXPAXLI For Treatment Of Wet Age-Related Macular Degeneration
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular’s plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidenceAXPAXLI NDA submission
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs
On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report. Management confirmed that AXPAXLI, its lead retinal disease candidate, remains on track for a new drug application submission for wet age-related macular degeneration in the fourth quarter of 2026, a plan the […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Notman Donald | -1,099 | $10.24 | $11,254 |
| 2026-08-25 | Dugel Pravin | +50,092 | - | - |
| 2026-08-25 | Dugel Pravin | -50,092 | - | - |
| 2026-08-24 | Kaiser Peter | -3,035 | $10.77 | $32,687 |
| 2026-08-24 | Nayak Sanjay | -1,897 | $10.78 | $20,450 |
| 2026-08-24 | Heier Jeffrey S. | -3,296 | $10.78 | $35,531 |
| 2026-08-24 | Dugel Pravin | -21,649 | $10.77 | $233,160 |
| 2026-06-16 | Dugel Pravin | +50,092 | - | - |
| 2026-06-16 | Dugel Pravin | -50,092 | - | - |
| 2026-06-10 | Robins Jason Shand | +14,024 | - | - |
| 2026-06-10 | Robins Jason Shand | +15,441 | - | - |
| 2026-06-10 | Hong Seung Suh | +44,000 | - | - |
| 2026-06-10 | Hong Seung Suh | +14,000 | - | - |
| 2026-06-10 | Williams Leslie J. | +44,000 | - | - |
| 2026-06-10 | Williams Leslie J. | +14,000 | - | - |
| 2026-06-10 | Warden Charles M | +44,000 | - | - |
| 2026-06-10 | Warden Charles M | +14,000 | - | - |
| 2026-06-10 | Graves Adrienne L | +44,000 | - | - |
| 2026-06-10 | Graves Adrienne L | +14,000 | - | - |
| 2026-06-10 | LINDSTROM RICHARD L MD | +44,000 | - | - |
| 2026-06-10 | LINDSTROM RICHARD L MD | +14,000 | - | - |
| 2026-06-10 | RAINES MERILEE | +44,000 | - | - |
| 2026-06-10 | RAINES MERILEE | +14,000 | - | - |
| 2026-06-03 | Waheed Nadia | -14,828 | $8.27 | $122,628 |
| 2026-05-28 | Dugel Pravin | +394,696 | - | - |
| 2026-05-28 | Dugel Pravin | -394,696 | - | - |
| 2026-05-26 | Dugel Pravin | -21,156 | $8.2 | $173,479 |
| 2026-05-26 | Kaiser Peter | -2,967 | $8.2 | $24,329 |
| 2026-05-26 | Heier Jeffrey S. | -3,018 | $8.2 | $24,748 |
| 2026-05-26 | Nayak Sanjay | -1,858 | $8.2 | $15,236 |
| 2026-04-09 | Dugel Pravin | +394,696 | - | - |
| 2026-04-09 | Dugel Pravin | -394,696 | - | - |
| 2026-02-23 | Dugel Pravin | -20,056 | $8.28 | $166,064 |
| 2026-02-23 | Kaiser Peter | -2,810 | $8.28 | $23,267 |
| 2026-02-23 | Heier Jeffrey S. | -3,057 | $8.28 | $25,312 |
| 2026-02-23 | Nayak Sanjay | -1,759 | $8.28 | $14,565 |
| 2026-02-20 | Waheed Nadia | -3,510 | $7.74 | $27,167 |
| 2026-02-20 | LINDSTROM RICHARD L MD | +60,229 | $7.66 | $461,354 |
| 2026-02-12 | Notman Donald | -11,446 | $9.04 | $103,472 |
| 2026-02-12 | Nayak Sanjay | -10,348 | $9.04 | $93,546 |
| 2026-02-12 | Dugel Pravin | -124,882 | $9.04 | $1,128,933 |
| 2026-02-12 | Waheed Nadia | -7,863 | $9.04 | $71,082 |
| 2026-02-04 | Notman Donald | -6,035 | $8.54 | $51,539 |
| 2026-02-02 | Notman Donald | -5,455 | $9.14 | $49,859 |
| 2026-01-21 | Robinson David Wayne | +416,000 | - | - |
| 2026-01-21 | Robinson David Wayne | +136,000 | - | - |
| 2026-01-20 | Robins Jason Shand | +33,000 | - | - |
| 2026-01-02 | Anderman Todd | +197,650 | - | - |
| 2026-01-02 | Anderman Todd | +64,900 | - | - |
| 2026-01-02 | Meyers Steve Lawrence | +197,650 | - | - |
| 2026-01-02 | Meyers Steve Lawrence | +64,900 | - | - |
| 2026-01-02 | Nayak Sanjay | +197,650 | - | - |
| 2026-01-02 | Nayak Sanjay | +64,900 | - | - |
| 2026-01-02 | Kaiser Peter | +240,932 | - | - |
| 2026-01-02 | Kaiser Peter | +79,112 | - | - |
| 2026-01-02 | Saroj Namrata | +240,932 | - | - |
| 2026-01-02 | Saroj Namrata | +79,112 | - | - |
| 2026-01-02 | Waheed Nadia | +240,932 | - | - |
| 2026-01-02 | Waheed Nadia | +79,112 | - | - |
| 2026-01-02 | Heier Jeffrey S. | +240,932 | - | - |
| 2026-01-02 | Heier Jeffrey S. | +79,112 | - | - |
| 2026-01-02 | Notman Donald | +240,932 | - | - |
| 2026-01-02 | Notman Donald | +79,112 | - | - |
| 2025-11-26 | Dugel Pravin | +49,754 | - | - |
| 2025-11-26 | Dugel Pravin | -49,754 | - | - |
| 2025-11-24 | Nayak Sanjay | -1,878 | $12.04 | $22,611 |
| 2025-11-24 | Dugel Pravin | -19,530 | $12.04 | $235,141 |
| 2025-11-24 | Kaiser Peter | -3,007 | $12.02 | $36,144 |
| 2025-11-24 | Heier Jeffrey S. | -3,469 | $12.04 | $41,767 |
| 2025-11-05 | Saroj Namrata | -25,865 | $10.74 | $277,790 |
| 2025-10-08 | Anderman Todd | -11,132 | $12.34 | $137,369 |